Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
Aug. 31, 2012
|
1 min read
Aug. 31, 2012
|
1 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
March 2, 2012
|
1 min read